Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT02941731Phase 1Completed
Phase 1, randomised, open-label trial of oseltamivir in influenza (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Oseltamivir Cmax, Oseltamivir AUClast and 1 more. Started Apr 2015; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT02941731.